Complete financial analysis of ViewRay, Inc. (VRAY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ViewRay, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- China Foods Holdings Ltd. (CFOO) Income Statement Analysis – Financial Results
- China Renaissance Holdings Limited (CSCHF) Income Statement Analysis – Financial Results
- QAD Inc. (QADB) Income Statement Analysis – Financial Results
- Jeudan A/S (JDAN.CO) Income Statement Analysis – Financial Results
- PRG Corporation Public Company Limited (PRG.BK) Income Statement Analysis – Financial Results
ViewRay, Inc. (VRAY)
About ViewRay, Inc.
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, France, Taiwan, the United Kingdom, and internationally. The company provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 102.21M | 70.12M | 57.02M | 87.78M | 80.96M | 34.04M | 22.24M | 10.39M | 0.00 | 3.16M |
| Cost of Revenue | 92.16M | 69.78M | 61.08M | 93.26M | 74.36M | 27.71M | 25.87M | 14.54M | 0.00 | 8.19M |
| Gross Profit | 10.05M | 335.00K | -4.06M | -5.48M | 6.60M | 6.33M | -3.63M | -4.15M | 0.00 | -5.03M |
| Gross Profit Ratio | 9.83% | 0.48% | -7.12% | -6.24% | 8.16% | 18.60% | -16.32% | -39.98% | 0.00% | -159.16% |
| Research & Development | 32.43M | 31.85M | 25.01M | 23.79M | 16.52M | 14.71M | 11.44M | 10.45M | 0.00 | 8.78M |
| General & Administrative | 52.44M | 56.09M | 61.73M | 65.72M | 50.11M | 31.38M | 23.50M | 21.69M | 0.00 | 9.51M |
| Selling & Marketing | 30.49M | 16.04M | 15.18M | 25.81M | 15.06M | 8.41M | 5.60M | 5.14M | 0.00 | 3.78M |
| SG&A | 82.93M | 72.14M | 76.91M | 91.52M | 65.18M | 39.79M | 29.10M | 26.82M | 0.00 | 13.29M |
| Other Expenses | 3.17M | -2.17M | 585.00K | 3.20M | 6.39M | -16.77M | -512.00K | -117.00K | 0.00 | 0.00 |
| Operating Expenses | 115.36M | 103.98M | 101.92M | 115.32M | 81.70M | 54.50M | 40.55M | 37.27M | 0.00 | 22.07M |
| Cost & Expenses | 207.52M | 173.77M | 162.99M | 208.58M | 156.05M | 82.21M | 66.41M | 51.82M | 0.00 | 30.26M |
| Interest Income | 1.69M | 13.00K | 791.00K | 1.72M | 8.00K | 5.00K | 2.00K | 2.00K | 0.00 | 4.00K |
| Interest Expense | 5.06M | 4.24M | 3.31M | 4.33M | 7.70M | 7.25M | 5.95M | 3.45M | 0.00 | 97.00K |
| Depreciation & Amortization | 4.85M | -2.16M | 1.38M | 4.92M | 3.50M | 2.20M | 1.71M | 1.26M | 0.00 | 1.15M |
| EBITDA | -100.46M | -105.81M | -104.60M | -115.87M | -68.70M | -62.73M | -44.69M | -41.54M | 0.00 | -26.04M |
| EBITDA Ratio | -98.29% | -150.90% | -183.46% | -132.00% | -84.85% | -184.28% | -200.95% | -399.83% | 0.00% | -824.34% |
| Operating Income | -107.13M | -103.65M | -105.98M | -120.80M | -75.09M | -48.16M | -44.18M | -41.43M | 0.00 | -27.10M |
| Operating Income Ratio | -104.81% | -147.82% | -185.87% | -137.61% | -92.75% | -141.48% | -198.66% | -398.72% | 0.00% | -857.77% |
| Total Other Income/Expenses | -203.00K | -6.40M | -1.93M | 596.00K | -1.30M | -24.01M | -6.46M | -3.57M | 0.00 | -125.00K |
| Income Before Tax | -107.33M | -110.05M | -107.91M | -120.20M | -76.40M | -72.18M | -50.64M | -44.99M | 0.00 | -27.22M |
| Income Before Tax Ratio | -105.01% | -156.94% | -189.26% | -136.93% | -94.36% | -212.02% | -227.71% | -433.05% | 0.00% | -861.73% |
| Income Tax Expense | 203.00K | -3.91M | -2.53M | 2.87M | 1.30M | -9.52M | 3.73M | 1.00K | 0.00 | 0.00 |
| Net Income | -107.53M | -106.13M | -105.38M | -123.07M | -76.40M | -72.18M | -50.64M | -45.00M | 0.00 | -27.22M |
| Net Income Ratio | -105.21% | -151.36% | -184.82% | -140.20% | -94.36% | -212.02% | -227.71% | -433.06% | 0.00% | -861.73% |
| EPS | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| EPS Diluted | -0.60 | -0.65 | -0.71 | -1.21 | -0.94 | -1.23 | -1.26 | -2.58 | 0.00 | -33.39 |
| Weighted Avg Shares Out | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
| Weighted Avg Shares Out (Dil) | 180.70M | 164.52M | 147.90M | 102.00M | 81.12M | 58.46M | 40.07M | 17.43M | 892.32K | 815.34K |
ViewRay Announces Fourth Quarter and Full Year 2022 Results
DENVER , Feb. 27, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 2022 Highlights Total revenue of $102.2 million primarily from...
ViewRay: Sales, Order Momentum Ratcheting Higher
ViewRay has continued growth in order momentum. Its stock price has moved sideways into the new year, adding another attractive entry point.
ViewRay Announces Conference Call for Fourth Quarter 2022 Financial Results to be Held After Market on February 27, 2023
DENVER , Jan. 31, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today details relating to the release of fourth quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Monday, February 27, 2023 at 4:30...
ViewRay Enters into Cooperation Agreement with Hudson Executive Capital
CLEVELAND , Jan. 20, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that it has reached an agreement with Hudson Executive Capital LP ("HEC") to appoint Sai Nanduri, Senior Investment Analyst and representative of HEC, as an observer of the...
Findings Published in JAMA Oncology Demonstrate Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer
MIRAGE phase III randomized controlled trial shows a significant reduction in GU and GI toxicities with MRIdian® MRI-guided versus CT-guided SBRT DENVER , Jan. 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that findings from the phase III...
ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer
DENVER , Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject...
Chindex Medical Acquires 10 ViewRay MRIdian® Systems for Advanced Cancer Treatment
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China DENVER , Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy...
University Hospitals in Cleveland Enters into Master Purchase Agreement with ViewRay for Multiple MRIdian® Systems
Immediate order of one system with ability to purchase an additional three systems DENVER , Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the University Hospitals (UH) Seidman Cancer Center in Cleveland has selected a MRIdian...
ViewRay: Revise Thesis To Buy, Multiple Upside Targets In Place
Revised FY22 revenue guidance with management more confident on the lower end of range. Backlog continues to grow, ending 26% higher to $350mm for the third quarter.
ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility
Facility includes senior secured term loan of up to $100 million and a revolving line of credit of up to $25 million DENVER , Nov. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced that it has...
Source: https://incomestatements.info
Category: Stock Reports